| Recruiting | An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma NCT07493044 | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 |
| Recruiting | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes NCT07321067 | Ahmed Karam Helmy | — |
| Not Yet Recruiting | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Tr NCT07282509 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on NCT07147101 | Fudan University | — |
| Recruiting | Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma NCT07123545 | Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma NCT06902389 | Eastern Hepatobiliary Surgery Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) NCT07039201 | Zhejiang University | N/A |
| Recruiting | A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatoc NCT06828380 | National Cancer Center, Korea | Phase 2 |
| Recruiting | Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma NCT06995105 | Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular NCT06737913 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellul NCT06749678 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Recruiting | Phase 2 Study of WGI-0301 for Advanced HCC NCT06309485 | Zhejiang Haichang Biotech Co., Ltd. | Phase 2 |
| Unknown | The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arte NCT05862181 | Peking University Cancer Hospital & Institute | — |
| Terminated | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With L NCT05375604 | Codiak BioSciences | Phase 1 |
| Terminated | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatmen NCT04985136 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC NCT04723004 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib NCT04344158 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Active Not Recruiting | Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC NCT04523493 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Terminated | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer NCT04212221 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripali NCT04605796 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Completed | Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) NCT02906397 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC NCT02814461 | Shin Kong Wu Ho-Su Memorial Hospital | Phase 1 |
| Unknown | Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular C NCT02509169 | Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 |
| Terminated | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC NCT01101906 | Astellas Pharma Inc | Phase 2 |